Wedbush reiterates Telix Pharmaceuticals stock rating at $22 target
Wedbush reiterated an Outperform rating and $22 price target for Telix Pharmaceuticals (TLX) after its Capital Markets Day. The company reaffirmed 2026 revenue guidance of $950M-$970M and expects $1.5B in 2027 revenue, including $300M from ITM. TLX reported 1H 2026 revenue of AUD 477M, up 22% YoY, with net profit of AUD 38M. The company has three FDA-approved imaging products and aims for six by this time next year.
How this was made
The 30-second read
Why it matters
The upgraded rating and higher target provide a fresh catalyst for TLX, likely prompting short‑term buying pressure.
Market read
Analyst upgrade with a substantial price target increase creates a near‑term trading opportunity for TLX.
What to watch
Potential regulatory delays or trial setbacks could temper the upside.
Background
Wedbush's reiteration follows Telix's Capital Markets Day where it outlined revenue guidance and pipeline progress.
Ticker impact
Wedbush reiterated an Outperform rating and raised its price target to $22, up from prior levels, indicating fresh analyst optimism.
likely upward pressure as investors price in the higher target
The new $22 target represents a 144% upside from the current $9.03 price, providing a clear catalyst for short‑term buying.
Market effects
Positive sentiment may spill over to other precision‑medicine and imaging biotech stocks.
Limited to US‑listed biotech sector.
Modest; primarily affects TLX and peers.
Counterpoint
The target may be overly optimistic given the company's cash burn and reliance on upcoming trial data.
Key entities
- companyTelix Pharmaceuticals Ltd
US‑listed biotech focused on precision‑medicine imaging.
- analystWedbush Securities
Equity research firm that issued the rating and target.


